CSPC PHARMA (01093): ALMB-0166 has received clinical trial approval in China for the treatment of Parkinson's disease.

CSPC PHARMA (01093) announced that ALMB-0166 developed by the group has been approved by the China National Medical Products Administration for Phase II clinical trials in China to evaluate its effectiveness in patients with Parkinson's disease. ALMB-0166 is a first-in-class humanized monoclonal antibody inhibitor targeting the novel target Connexin 43 (Cx43), developed independently by the company's subsidiary AlaMab Therapeutics Inc., for the treatment of neurological diseases such as Parkinson's disease, acute ischemic stroke, and acute spinal cord injury. Parkinson's disease is the second largest neurodegenerative disease globally, characterized by progressive degeneration of dopaminergic neurons in the substantia nigra and formation of Lewy bodies. The cause of Parkinson's disease is not yet fully understood, with symptoms including resting tremors, muscle rigidity, bradykinesia, postural instability, as well as non-motor symptoms such as sleep disturbances, cognitive and psychiatric disorders. These symptoms worsen as the disease progresses, significantly impacting the quality of life of patients and imposing a heavy economic and caregiving burden on families and society. Current treatments for Parkinson's disease focus on symptom relief and do not reverse the progression of the disease or achieve a cure. Therefore, there is an urgent need in the field of Parkinson's disease for the development of new therapeutic drugs and approaches to effectively slow disease progression and improve patient quality of life. ALMB-0166 targets Cx43 hemichannels to inhibit the release and spread of neuroinflammatory factors, maximizing protection of the nervous system. Preclinical studies in subacute and chronic Parkinson's disease animal models have shown that ALMB-0166 significantly inhibits the decrease in dopamine levels in the brains of animals, restoring their behavioral and functional abilities, with a good dose/response relationship. The group will spare no effort in advancing clinical research on ALMB-0166 for different indications, aiming for its expedited market approval.